<!--StartFragment-->

**AMR in Cancer Epidemiology**

Antimicrobial resistance (AMR) has emerged as a critical issue in global public health, affecting not only infectious diseases but also complicating cancer treatment and outcomes (Nanayakkara _et al_., 2021). AMR in cancer epidemiology refers to the resistance of microorganisms to antimicrobial agents essential for managing infections in cancer patients, which increases the risk of infections in an already vulnerable population, posing significant challenges to cancer treatment efficacy and patient survival (Teillant _et al_., 2015).

Cancer patients are at a higher risk of infections due to immunosuppression from chemotherapy, radiation, and the disease itself (Nanayakkara _et al_., 2021). Frequent use of antibiotics in this population whether for prophylactic or therapeutic purposes, can select for resistant strains, creating a cycle of resistance that is difficult to break. Also, patients with cancer are vulnerable to healthcare-acquired infections as a major source of antibiotic-resistant organisms due to their prolonged stay in intensive care units (Teillant _et al_., 2015). These infections are often treated with broad-spectrum antibiotics. However, the rising prevalence of AMR has rendered many standard antibiotics less effective, leading to increased frequency of sepsis, sepsis-related mortality, and increased cost of cost in cancer patients (Montassier _et al_., 2013). A study by Cornejo-Juárez _et al_. (2015) found that hospital-acquired infections were the cause of 58 out of 282 fatalities (23%) among cancer patients who needed critical care. Of the 58 cases, 51 (88%), had an MDR pathogen identified. Similarly, Bodro _et al_. (2014) found that cancer patients with infections caused by antibiotic-resistant ESKAPE pathogens experienced higher rates of persistent bacteremia, metastatic infection, and early mortality compared to those with other bacterial infections. Risk factors for these resistant infections included comorbidities, prior antibiotic use, urinary catheters, and urinary tract infections, with pathogens such as MRSA, ESBL-producing _K. pneumoniae_, and carbapenem-resistant _P. aeruginosa_ being prevalent.

With the increase in AMR in infections affecting cancer patients, the effectiveness of first-line treatments has been compromised, leading to the use of more toxic and expensive alternatives, which further strain healthcare resources and negatively impact patient quality of life (Bodro _et al_., 2014). The implications of AMR in cancer epidemiology extend beyond individual patient outcomes, influencing public health strategies and cancer care protocols. Addressing this issue requires a multidimensional approach, including stewardship programs to reduce unnecessary antibiotic use, development of new antimicrobial agents, and integration of AMR considerations into cancer epidemiology research. 

In conclusion, AMR represents a significant and complex challenge in cancer epidemiology. As the prevalence of drug-resistant infections continues to rise, the oncology community must prioritize research and policy efforts that address AMR, ensuring that cancer patients receive the best possible care in the face of this evolving threat.

**References**

Bodro, M., Gudiol, C., Garcia-Vidal, C., Tubau, F., Boix, L., Domingo-Domenech, E., & Carratalà, J. (2014). Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients. _Supportive Care in Cancer_, _22_, 603-610.

Cornejo-Juárez, P., Vilar-Compte, D., Pérez-Jiménez, C., Ñamendys-Silva, S. A., Sandoval-Hernández, S., & Volkow-Fernández, P. (2015). The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit. _International Journal of Infectious Diseases_, _31_, 31-34.

Montassier, E., Batard, E., Gastinne, T., Potel, G., & de La Cochetière, M. F. (2013). Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. _European journal of clinical microbiology & infectious diseases_, _32_, 841-850.

Nanayakkara, A. K., Boucher, H. W., Fowler Jr, V. G., Jezek, A., Outterson, K., & Greenberg, D. E. (2021). Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward. _CA: a cancer journal for clinicians_, _71_(6), 488-504.

Teillant, A., Gandra, S., Barter, D., Morgan, D. J., & Laxminarayan, R. (2015). Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. _The Lancet infectious diseases_, _15_(12), 1429-1437.

\


<!--EndFragment-->
